The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: A need for more research

Consultant Pharmacist

Volumn 25, Issue 1, 2010, Pages 41-54

  Assimon, Magdalene M ^a   Mousa, Shaker ^b   Shaker, Olfat ^c   Pai, Amy Barton ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Pharmaceutical Research Institute   (United States)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Hemodialysis; Mortality; Phosphate binders; Sevelamer

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D;

ADD ON THERAPY; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BONE METABOLISM; BONE MINERALIZATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY CALCIFICCATION; DISEASE ASSOCIATION; DRUG EFFICACY; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MINERAL METABOLISM; MORTALITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SURVIVAL RATE;

ACETATES; CALCIUM CARBONATE; CALCIUM COMPOUNDS; CARDIOVASCULAR DISEASES; CHELATING AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; POLYAMINES; RENAL DIALYSIS;

EID: 75849138472     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2010.41     Document Type: Review

References (59)

1. United States Renal Data System 2007. Annual data report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease; 2007.
2. Martin KJ, Gonzalez EA. Strategies to minimize bone disease in renal failure. Am J Kidney Dis 2001;38:1430-6.
3. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 2006;69:1945-53.
4. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and CV disease in hemodialysis patients. The USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005;16:1788-93.
5. Foley RN, Culleton BF, Parfrey PS et al. Cardiac disease in diabetic end-stage renal disease. Diabetologia 1997;40:1307-12.
6. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83.
7. National Kidney Foundation. Kidney disease outcome quality initiative clinical practice guidelines for CV disease in dialysis patients. Am J Kidney Dis 2005;45:1-153.
8. Sarnak MJ, Levey AS. Epidemiology of cardiac disease in dialysis patients. Semin Dial 1999;12:69-76.
9. Stenvinkel P, Carrero JJ, Axelsson J et al. Emerging biomarkers for evaluating CV risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008;3:505-21.
10. McCullough PA, Agrawal V, Danielewicz E et al. Accelerated atherosclerotic calcification and Monckeberg's sclerosis: a continuum of advanced vascular pathology in chronic kidney disease. Blood Purif 2005;23:12-9.
11. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17.
12. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18.
13. National Kidney Foundation. Kidney disease outcome quality initiative clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kid Dis 2003;42:1-201.
14. Chertow GM, Burke SK, Lazarus M et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997;29:66-71.
15. Goldberg DI, Dillon MA, Slatopolsky EA et al. Effect of renagel, a non absorbed, calcium- and aluminum-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease. Nephrol Dial Transplant 1998;13:2303-10.
16. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 1999;55:299-307.
17. Chertow GM, Burke SK, Dillon MA et al. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of hacmodialysis patients. Neph Dial Transplant 1999;14:2907-14.
18. Qunibi WY, Hootkins RE, McDowell LL et al. Treatment of hyperphosphatemia in hemodialysis patients: the calcium acetate renagel evaluation. Kidney Int 2004;65:1914-26.
19. Koiwa F, Onoda N, Kato H et al. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial 2005;9:340-6.
20. Brewster UC, Ciampi MA, Abu-Alfa AK et al. Long-term comparison of sevelamer hydrochloride to calcium-based phosphate binders. Nephrology (Carlton) 2006;11:142-6.
21. McCoullough PA, Sandberg KR, Durnier F et al. Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease. J Nephrol 2004;17:205-15.
22. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52.
23. Chertow GM, Raggi P, McCarthy JT et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic vascular disease in hemodialysis patients. Am J Nephrol 2003;23:307-14.
24. Chertow GM, Raggi P, Chasan-Taber S et al. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;19:1489-96.
25. Braun J, Asmus HG, Hoizer H et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate - phosphorus metabolism and CV calcification. Clin Nephrol 2004;62:104-15.
26. Asmus HG, Braun J, Krause R et al. Two year comparision of sevelamer and calcium carbonate effects on CV calcification and bone density. Nephrol Dial Transplant 2005;20:1653-61.
27. Galassi A, Speigel DM, Bellasi A et al. Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrol Dial Transplant 2006;21:3215-22.
28. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-24.
29. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the dialysis outcomes and practice patterns study. Kidney Int 2005;67:1179-87.
30. Klemmer PJ. Calcium loading, calcium accumulation, and associated CV risks in dialysis patients. Blood Purif 2005;23:12-9.
31. Braun J, Oldendorf M, Moshage W et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996;27:394-401.
32. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the dialysis outcomes and practice patterns study. Am J Kidney Dis 2008;52:519-30.
33. Davies MR, Hruska KA. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 2001;60:472-9.
34. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 2004;95:560-7.
35. Cannata-Andía JB, Rodríguez-García M, Carrillo López N et al. Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol 2006;12:267-73.
36. Schwarz U, Buzello M, Ritz E et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000;15:218-23.
37. Adragao T, Pires A, Lucas C et al. A simple vascular calcification score predicts CV risk in haemodialysis patients. Nephrol Dial Transplant 2004;19:1480-8.
38. Jono S, McKee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000;87:10-7.
39. Giachelli CM, Jono S, Shioi A et al. Vascular calcification and inorganic phosphate. Am J Kidney Dis 2001;38:34-7.
40. Marchais SJ, Metivier F, Guerin AP et al. Association of hyperphosphatemia with haemodynamic disturbances in end-stage renal disease. Nephrol Dial Transplant 1999;14:2178-83.
41. Galetta F, Cupisti A, Franzoni F et al. Left ventricular function and calcium phosphate plasma levels in uraemic patients. J Intern Med 2005;258:378-84.
42. Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol 2006;1:697-703.
43. Sigrist M, Bungay P, Maarter W et al. Vascular calcification and CV function in chronic kidney disease. Nephrol Dial Transplant 2006;21:707-14.
44. Blacher J, Safar ME, Guerin AP et al. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int. 2003;63:1852-60.
45. Blacher J, Guerin AP, Pannier B et al. Arterial calcifications, arterial stiffness, and CV risk in end-stage renal disease. Hypertension 2001;38:938-42.
46. Blacher J, Guerin AP, Pannier B et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999;99:2434-9.
47. Guerin AP, London GM, Marchais SJ et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014-21.
48. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and CV disease? J Am Coll Cardiol 2002;39:695-701.
49. Friedman EA. An introduction to phosphate binders for the treatment of hyperphosphatemia in patients with chronic kidney disease. Kidney Int Suppl 2005:2-6.
50. Salusky IB, Goodman WG. Cardiovascular calcification in end stage renal disease. Nephrol Dial Transplant 2002;17:336-9.
51. Matsuoka M, Iseki K, Tamashiro M et al. Impact of high coronary artery calcification score on survival in patients on chronic hemodialysis. Clin Exp Nephrol 2004;8:54-8.
52. Block GA, Bellasi A, Kooienga L et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-41.
53. Marangon N, Lindholm B, Stenvinkel P. Nonphosphate-binding effects of sevelamer - are they of clinical relevance? Semin Dial 2008;21:385-9.
54. Caglar K, Yilmaz MI, Saglam M et al. Short-term treatment with sevelamer increases serum fetuin - a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008;3:61-8.
55. Qunibi W, Moustafa M, Muenz L et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 study. Am J Kidney Dis 2008;51:952-65.
56. Suki WN, Cangiano JL, Reed J et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-7.
57. St Peter WL, Liu J, Weinhandl E et al. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008;5:445-54.
58. Borzecki AM, Lee A, Wang SW et al. Survival in end stage renal disease: calcium carbonate vs. sevelamer. J Clin Pharm Ther 2007;32:617-24.
59. Huybrechts KF, Caro JJ, Wilson DA et al. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value Health 2005;8:549-61.